Form 4: Benitec Biopharma Director Exercises Warrants and Disposes of Shares
SEC Form 4 Filing
J. Kevin Buchi, a director of Benitec Biopharma Inc., exercised warrants to acquire 51,813 shares of common stock and disposed of the same amount on February 27, 2025.
Summary
- On February 27, 2025, J. Kevin Buchi, a director of Benitec Biopharma Inc., executed a transaction involving the company's common stock.
- Buchi exercised common warrants at a price of $3.86, acquiring 51,813 shares.
- Concurrently, Buchi disposed of 51,813 shares of common stock.
- Following these transactions, Buchi directly owns 103,910 shares of Benitec Biopharma Inc.
Sentiment
Score: 5
Explanation: This is a neutral filing, simply reporting a transaction by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates changes in the director's holdings of Benitec Biopharma stock.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it reflects insider activity, but the volume is relatively small.
Key Dates
| Date | Description |
|---|---|
| 08/11/2023 | Date exercisable for Common Warrants |
| 02/27/2025 | Date of transaction: exercise of warrants and disposal of shares. |
| 03/03/2025 | Date of signature for the Form 4 filing. |
| 08/11/2028 | Expiration date for Common Warrants |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.